Amgen Provides Ambitious Update On Biosimilars Business

CEO Says Company Expects To Double Biosimilar Revenues To Around $4bn By 2030

Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.

Amgen offices at Cambridge Science Park
Amgen has restated its ambitions to double the value of its biosimilars business by 2030 • Source: Alamy

Amgen, Inc. has provided an update on its biosimilars business during a management discussion at the 40th annual J.P. Morgan Healthcare Conference, anticipating “a steady flow of launches that should enable us to grow that business as well through the end of the decade.”

“We expect to be able to grow the franchise as we launch new products and as we enter new geographic...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.